SC
LPCN icon

Stempoint Capital’s Lipocine LPCN Stock Holding History

Stempoint Capital’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28M Buy
+160,420
New +$1.4M 0.25% 61

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stempoint Capital's LPCN Position: Q1 2026 in Review

Stempoint Capital opened a new position in Lipocine (LPCN) in Q1 2026: 160,420 shares worth $1.28M. The stake represents 0.25% of the portfolio and ranks #61 among its holdings.

47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Stempoint Capital held 160,420 shares of Lipocine worth $1.28M as of Q1 2026.
  • Lipocine was a new Stempoint Capital position in Q1 2026.
  • Lipocine made up 0.25% of Stempoint Capital's portfolio in Q1 2026, its #61 holding.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.